With the strength of sales in GLP-1 weight loss drugs Mounjaro and Zepbound, Eli Lilly is now the first pharmaceutical ...

Eli Lilly and Company made history on Friday, November 21, 2025, becoming the first healthcare company to achieve a $1 trillion market capitalization. The pharmaceutical giant briefly crossed this ...

In a growing trend, some users of GLP-1 medications are hailing their results with microdosing, taking ...

The pancreas may be small, but it's essential to robust health. There are a number of everyday habits that may be harming ...

Chemerin is a key adipokine that regulates lipid metabolism and insulin sensitivity, and thus is involved in many metabolic ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

It’s just the latest landmark for Indianapolis-based Lilly, which was catapulted into the top spot as the world’s largest ...

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported in the results of a clinical trial.

Obesity should not be considered a barrier for a patient who needs a shoulder replacement procedure, researchers argued in a ...

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...